Session » Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

Date: Tuesday, October 23, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2402

Acoustic Emissions Generated By the Temporomandibular Joint of Patients with Juvenile Idiopathic Arthritis and Their Implication on Patient Assessment and Screening: A Pilot Study

9:00AM-11:00AM: Abstract Number: 2394

Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching

9:00AM-11:00AM: Abstract Number: 2392

Are Single Nucleotide Polymorphisms in Methotrexate Transporter Proteins Associated with Methotrexate Intolerance in Juvenile Idiopathic Arthritis?

9:00AM-11:00AM: Abstract Number: 2388

Assessment of Treatment Responses, with Special Reference to Remission Using Juvenile Arthritis Disease Activity Score (JADAS), in the Different Categories of Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2384

Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany

9:00AM-11:00AM: Abstract Number: 2399

Bone Density, Structure and Strength in Canadian Children and Youth with Juvenile Idiopathic Arthritis: The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

9:00AM-11:00AM: Abstract Number: 2398

Children with Enthesitis Have Worse Quality of Life, Function, and Pain, Irrespective of Their Juvenile Arthritis Category

9:00AM-11:00AM: Abstract Number: 2406

Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents

9:00AM-11:00AM: Abstract Number: 2408

Comparison of the Tear Cytokine and Chemokine Profile of Children with JIA and JIA-Associated Uveitis

9:00AM-11:00AM: Abstract Number: 2389

Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)

9:00AM-11:00AM: Abstract Number: 2405

Health-Related Quality of Life, Functioning, and Mental Health of Children with Chronic Non-Infectious Uveitis

9:00AM-11:00AM: Abstract Number: 2390

Incidence of and Risk Factors for Adrenal Suppression Following Ultrasound-Guided Intra-Articular Corticosteroid Injection with Triamcinolone Acetonide in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2393

Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?

9:00AM-11:00AM: Abstract Number: 2381

Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years

9:00AM-11:00AM: Abstract Number: 2379

Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2391

Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients

9:00AM-11:00AM: Abstract Number: 2407

New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2383

Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry

9:00AM-11:00AM: Abstract Number: 2404

Quality of Life Assessment in Juvenile Idiopathic Arthritis: A Single Center Assessment

9:00AM-11:00AM: Abstract Number: 2382

Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan

9:00AM-11:00AM: Abstract Number: 2396

Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients

9:00AM-11:00AM: Abstract Number: 2387

Resurrecting Triamcinolone Hexacetonide (the Steroid Formerly Known as Aristospan®): Efficacy and Safety of a Compounded Preparation of Triamcinolone Hexacetonide for Intra-Articular Injection in Children with Arthritis

9:00AM-11:00AM: Abstract Number: 2386

Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment

9:00AM-11:00AM: Abstract Number: 2378

Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category

9:00AM-11:00AM: Abstract Number: 2385

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices

9:00AM-11:00AM: Abstract Number: 2401

The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study

9:00AM-11:00AM: Abstract Number: 2397

The Impact of Adalimumab on Growth in Patients with Pediatric Enthesitis-Related Arthritis

9:00AM-11:00AM: Abstract Number: 2380

The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry

9:00AM-11:00AM: Abstract Number: 2403

The Therapeutic Alliance Is Associated with a Better Therapeutic Adherence in Children with Juvenile Idiopathic Arthritis: Results of a French Multicenter Study

9:00AM-11:00AM: Abstract Number: 2395

Tumor Necrosis Factor-α Inhibitor (TNFi)-Induced Psoriasis: Prevalence and Response to Therapy in Patients with Juvenile Idiopathic Arthritis (JIA) in Two Children’s Hospitals

9:00AM-11:00AM: Abstract Number: 2400

Validating and Developing a Selected Questionnaire to Predict Early Diagnosis of Juvenile Idiopathic Arthritis in German Population

« View all sessions from this meeting